---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-335016"
form_type: "8-K"
ticker: "MNKD"
cik: "0000899460"
company_name: "MANNKIND CORP"
filed_at: "2026-08-05T20:03:26+00:00"
generated_at: "2026-08-05T20:04:19.853105+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MannKind Q2 2026 revenue $109.4M (+43% YoY); Afrezza pediatric and Furoscix ReadyFlow approved

## Summary
- Q2 total revenue $109.4M, up 43% YoY; Furoscix contributed $22.2M in net sales.
- Afrezza net sales $17.0M (-7% YoY); pediatric indication approved May 29, early launch momentum.
- Furoscix ReadyFlow autoinjector approved July 23; commercial launch expected late August.
- Positive Phase 1b data for nintedanib DPI (MNKD-201) in IPF; global Phase 2 enrolling.
- Closed $50M private placement to fund $45M CVR payment from Furoscix ReadyFlow approval.

## SEC filing metadata
- accession: 0001193125-26-335016
- form_type: 8-K
- ticker: MNKD
- cik: 0000899460
- company_name: MANNKIND CORP
- filed_at: 2026-08-05T20:03:26+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899460/000119312526335016/0001193125-26-335016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899460/000119312526335016/mnkd-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-335016
- JSON: https://secwatch.observer/filing/0001193125-26-335016.json
- Plain text: https://secwatch.observer/filing/0001193125-26-335016.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.